

**SMS PHARMACEUTICAL LIMITED**  
**417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad - 500 038**  
**Un-Audited Financial Results for the Quarter Ended 31st March, 2009**

(Rs.in lakhs)

S.No.	Particulars	Quarter Ended		Year Ended	
		31-03-2009	31-03-08	31-03-2009	31-03-08
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	(a) Net sales/Income from Operations	4,757.03	5,704.33	24,482.83	21,040.67
	(b) Other Operating Income	-	-	-	-
2	Expenditure				
	a. Increase/decrease in stock in trade and work in progress	694.38	(130.32)	(122.05)	(932.97)
	b. Consumption of raw materials	2,728.14	2,793.12	15,346.82	11,926.58
	c. Purchase of traded goods	635.86	679.72	2,574.25	2,313.79
	d. Employees cost	226.94	262.23	969.14	799.03
	e. Depreciation	140.57	104.63	566.34	517.95
	f. Other expenditure	735.71	1,014.77	3,182.42	2,997.94
	<b>Total - (a to f)</b>	<b>5,161.60</b>	<b>4,724.15</b>	<b>22,516.92</b>	<b>17,622.32</b>
3	Profit from Operations before Other Income, Interest and Exceptional Items (1) - (2)	(404.57)	980.18	1,965.91	3,418.35
4	Other Income	20.70	60.87	27.71	505.46
5	<b>Profit before interest &amp; Exceptional Items (3)+(4)</b>	<b>(383.87)</b>	<b>1,041.05</b>	<b>1,993.62</b>	<b>3,923.81</b>
6	Interest	406.28	166.72	1,276.11	686.54
7	<b>Profit after interest but before Exceptional Items (5)-(6)</b>	<b>(790.15)</b>	<b>874.33</b>	<b>717.51</b>	<b>3,237.27</b>
8	Exceptional items	-	-	-	-
9	<b>Profit from Ordinary Activities before Tax (7)+(8)</b>	<b>(790.15)</b>	<b>874.33</b>	<b>717.51</b>	<b>3,237.27</b>
10	Tax Expenses	79.30	(141.00)	79.30	521.21
11	<b>Net Profit from Ordinary Activities after Tax (9)-(10)</b>	<b>(869.45)</b>	<b>1,015.33</b>	<b>638.21</b>	<b>2,716.06</b>
12	Extraordinary items (net of Tax Expense )				-
13	<b>Net Profit / (Loss) for the period (11) -(12)</b>	<b>(869.45)</b>	<b>1,015.33</b>	<b>638.21</b>	<b>2,716.06</b>
14	Paid-up equity share capital Rs. 10/- per share	1,001.52	1,000.22	1,001.52	1,000.22
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				19,820.25
16	Earning Per Share (EPS)				
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	(8.68)	10.15	6.38	27.15
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	(8.68)	10.15	6.38	27.15
17	Public Shareholding				
	- Number of Shares	4,647,066	4,634,098	4,647,066	4,634,098
	- Percentage of Shareholding	46.40	46.33	46.40	46.33
18	Promoters and Promoters Group Shareholding:				
	a) Pledged/Encumbered	-	-	-	-
	- Number of Shares	-	-	-	-
	- Percentage of Shares	-	-	-	-
	b) Non-encumbered	5,368,137	5,368,137	5,368,137	5,368,137
	- Number of Shares				
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100
	- Percentage of Shares (as a % of the total share capital of the company)	53.60	53.67	53.60	53.67

**Notes:**

1. The above results were subject to "Limited Review" by the Statutory Auditors and were reviewed by the Audit Committee and have been approved by the board at its meeting held on 30th April, 2009.
2. Details of amount spent out of the funds raised, by IPO and other sources, during the previous year, as per clause 43 of listing agreement are furnished below :

(Rs. in Lakhs)		
Particulars	Details	Amount
Funds Received		13,871.06
Less: Utilised		
For New Project	9,211.92	
For working capital requirements	2,357.82	
For issue expenses	637.10	12,206.84
Funds unutilised as on 31st March, 2009 and in Deposits		1,664.22

3. The Company's business activity falls within a single primary business segment of "Bulk Drugs". Hence segment reporting is not applicable.
4. Provision towards Income Tax for the Quarter / Year ending 31st March, 2009 was considered to the extent of MAT Liability, taking in to consideration of benefit available U/s.35 (2AB) in respect of R&D expenditure and also benefits available U/s.72A with e
5. The Foreign Exchange Fluctuation loss included in the expenditure items for the quarter ending and also for the year ending 31-03-2009 was Rs.177.09 Lakhs and Rs.321.91 Lakhs respectively.
6. There has been no change in the accounting policies adopted during the quarter / year ended 31st March, 2009 as compared to those followed in the preceeding financial year 2007-08
7. Details of share holders complaints during the quarter ended 31st March, 2009 are:  
Beginning - 0; Received -3; Resolved -3 ; Pending - 0
8. Figures of previous periods have been regrouped / rearranged wherever necessary.

Place: Hyderabad  
Date : 30-04-2009

**for and on behalf of the Board of Directors of  
SMS Pharmaceuticlas Limited**

**P.Ramesh Babu  
Chairman & Managing Director.**